Fortrea Holdings Inc.

FTRE Healthcare Biotechnology

Fortrea Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 1.00% from fiscal 2024. In the quarter to June 2026, revenue fell 4.52%, EPS grew 96.6%, free cash flow grew 53.2% and total debt fell 10.3%, each against the same quarter a year earlier.

22.49 0.26 −1.14%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−19.2×
Dividend yield
—
F-score
3/9
Altman Z
−0.34
Beneish M
−4.60
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
0.62 0.33 0.58 0.28
P/FCF ratio
8.33 4.63 17.82 0.00
P/Operating CF
57.08 (51.87) 12.19 8.85
P/B ratio
3.15 1.68 2.79 1.32
EV/Sales
0.95 0.66 0.90 0.64
EV/EBITDA
37.56 56.75 742.94 0.00
EV/FCF
12.80 9.39 27.76 (138.83)
Current Ratio
0.96 0.95 0.98 1.00
Net Debt/EBITDA
25.75 55.24 154.08 90.48
Debt/Equity
2.01 2.00 1.87 1.94
Earnings Yield
(5.23%) (52.12%) (63.25%) (133.49%)
Free Cash Flow Yield
12.00% 21.59% 5.61% (1.65%)
Free Cash Flow per Share
0.23 (0.27) 1.33 0.87
Book value per Share
5.53 5.62 6.18 6.37
Free Cash Flow
21.90 (25.00) 121.60 79.50
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates